| pubmed-article:21058895 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21058895 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21058895 | lifeskim:mentions | umls-concept:C0002423 | lld:lifeskim |
| pubmed-article:21058895 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:21058895 | lifeskim:mentions | umls-concept:C0242339 | lld:lifeskim |
| pubmed-article:21058895 | lifeskim:mentions | umls-concept:C0023779 | lld:lifeskim |
| pubmed-article:21058895 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:21058895 | lifeskim:mentions | umls-concept:C0033105 | lld:lifeskim |
| pubmed-article:21058895 | lifeskim:mentions | umls-concept:C0332120 | lld:lifeskim |
| pubmed-article:21058895 | lifeskim:mentions | umls-concept:C0740230 | lld:lifeskim |
| pubmed-article:21058895 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:21058895 | pubmed:dateCreated | 2010-11-16 | lld:pubmed |
| pubmed-article:21058895 | pubmed:abstractText | The prevalence of atherogenic dyslipidaemia (AD) can be assessed using the lipid triad (low high-density lipoprotein cholesterol [HDL-C] < 35 mg/dl, high triglyceride (TG) levels (? 200 mg/dl) and a high total cholesterol HDL-C ratio (TC/HDL-C>5). The aim of the present analysis was (1) to describe the prevalence of the lipid triad, (2) to quantify the associated cardiovascular risk on the basis of the PROCAM score, and (3) to calculate the additional risk reduction that can be obtained by adding nicotinic acid (NA) to a pre-existing statin therapy (model based on the outcomes of a previous randomized controlled study). | lld:pubmed |
| pubmed-article:21058895 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21058895 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21058895 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21058895 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21058895 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21058895 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21058895 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21058895 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21058895 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21058895 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:21058895 | pubmed:issn | 1473-4877 | lld:pubmed |
| pubmed-article:21058895 | pubmed:author | pubmed-author:AssmannGerdG | lld:pubmed |
| pubmed-article:21058895 | pubmed:author | pubmed-author:SchulteHelmut... | lld:pubmed |
| pubmed-article:21058895 | pubmed:author | pubmed-author:PittrowDavidD | lld:pubmed |
| pubmed-article:21058895 | pubmed:author | pubmed-author:BestehornKurt... | lld:pubmed |
| pubmed-article:21058895 | pubmed:author | pubmed-author:SmolkaWenefri... | lld:pubmed |
| pubmed-article:21058895 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21058895 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:21058895 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21058895 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21058895 | pubmed:pagination | 2833-9 | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:meshHeading | pubmed-meshheading:21058895... | lld:pubmed |
| pubmed-article:21058895 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:21058895 | pubmed:articleTitle | Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. | lld:pubmed |
| pubmed-article:21058895 | pubmed:affiliation | Institute for Clinical Pharmacology, Public Health Association Saxony, Technical University Dresden, Germany. kurt_bestehorn@msd.de | lld:pubmed |
| pubmed-article:21058895 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21058895 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21058895 | pubmed:publicationType | Evaluation Studies | lld:pubmed |
